Chirurgický přístup k tumorům thalamu

Title in English Surgical Approaches to Thalamic Tumors


Year of publication 2015
Type Article in Periodical
Magazine / Source Česká a Slovenská neurologie a neurochirurgie
MU Faculty or unit

Faculty of Medicine

Field Neurology, neurosurgery, neurosciences
Keywords thalamic tumours; surgical approaches
Description Thalamic tumours are relatively rare lesions growing in a highly functional part of the brain. They are more frequent in paediatric population. Their surgery is challenging and associated with a risk of significant morbidity. Relatively benign nature of many of these tumours suggests that radical resection should be attempted. The approach has to be very carefully planned, sometimes with help of modern diagnostic methods such as DTI. Location and projection of the tumour in the thalamus plays an important role in selecting an approach. Material and methods: During 2005-2014 we operated on 13 patients with thalamic tumours, mean age 20.6 years (1-64 years). These were 10 males and three females. Another 15-year-old male patient is being observed. Transcortical approach was used 7x, transcallosal 4x, trans-sylvian 2x and supracerebellar infratentorial 1x. Results: Gross total resection was achieved in six cases, subtotal in four and partial in three. There were eight pilocytic astrocytomas, one subependymal giant cell astrocytoma, one diffuse astrocytoma G II and three glioblastomas.Two older patients with glioblas-tomas died six and nine month after operation. All other patiens are still alive with the mean follow-up 5 years. Neurological status after the operation was good except for one older patient with glioblastoma who developed severe hemiparesis and aphasia. Conclusion:Thalamic tumours might be safely radically resected if correct approach is used. The choice of approach is based on the projection of the tumour. Smaller tumours that are not reach thalamic surface might be followed up or biopsied if there is a likelihood of their malignant nature. Oncological treatment should be reserved to malignant tumours.

You are running an old browser version. We recommend updating your browser to its latest version.

More info